atrial fibrillation deep venous thrombosis other pulmonary embolism venous thromboembolism
Conditions
Interventions
One group is dosed using tablets of 0.5 milligrams of acenocoumarol, while the
other group uses the regular 1.0 milligram tablets. Both will be dose-adjusted
to their previously determined INR targe
atrial fibrillation
heart valve repair
other diseases with an indication for anticoagulation
venous thrombo-embolism
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria:;- Men or women who use acenocoumarol for any indication, who are managed by Certe Trombosedienst - 80 years of age or older at time of inclusion - Using acenocoumarol with an average daily dose of less than 2 milligrams in the previous three months - Subject provided informed consent
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study:;- Initiated therapy with acenocoumarol in the last three months - Expected termination of VKA within six months - Dosing step lower than or equal to "step 7", i.e. usage of less than 7 milligrams acenocoumarol per 2 weeks - Patients who determine the acenocoumarol dose themselves
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is quality of anticoagulation (individual time in therapeutic range and INR variability). | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment satisfaction and number of medication errors. | — |
Countries
The Netherlands
Outcome results
None listed